Fig. 8: APOBEC3B in EGFR-driven lung tumor evolution.
From: The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
At tumor initiation, continuous APOBEC3B expression and activity induces CIN and p53 pathway activation, resulting in cell death. With targeted therapy, NF-κB induction leads to increased A3B expression, fueling TKI resistance. Figure created in BioRender.com.
